deﬁned by a vaccine-induced antibody. Proc. Natl Acad. Sci. USA 115, 168–173
(2018).
19. Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal inﬂuenza
vaccine: different approaches for one goal. Virol. J. 15, 17 (2018).
20. Nachbagauer, R. et al. A chimeric hemagglutinin-based universal inﬂuenza virus
vaccine approach induces broad and long-lasting immunity in a randomized,
placebo-controlled phase I trial. Nat. Med. 27, 106–114 (2021).
21. Orenstein, W. A. & Schaffner, W. Lessons learned: role of inﬂuenza vaccine pro-
duction, distribution, supply, and demand–what it means for the provider. Am. J.
Med. 121, S22–S27 (2008).
22. Felberbaum, R. S. The baculovirus expression vector system: a commercial
manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol. J.
10, 702–714 (2015).
23. Cox, M. M. & Hashimoto, Y. A fast track inﬂuenza virus vaccine produced in insect
cells. J. Invertebr. Pathol. 107, S31–S41 (2011).
24. Raymond, D. D. et al. Inﬂuenza immunization elicits antibodies speciﬁc for an
egg-adapted vaccine strain. Nat. Med. 22, 1465–1469 (2016).
25. Skowronski, D. M. et al. Low 2012-13 inﬂuenza vaccine effectiveness associated
with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in
circulating viruses. PLoS ONE 9, e92153 (2014).
26. Zost, S. J. et al. Contemporary H3N2 inﬂuenza viruses have a glycosylation site
that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc.
Natl Acad. Sci. USA 114, 12578–12583 (2017).
27. Flannery, B. et al. Interim estimates of 2016-17 seasonal inﬂuenza vaccine
effectiveness - United States, February 2017. MMWR Morb. Mortal. Wkly Rep. 66,
167–171 (2017).
28. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all inﬂuenza data - from
vision to reality. Euro surveillance: bulletin Europeen sur les maladies transmis-
sibles = European communicable disease bulletin 22, https://doi.org/10.2807/
1560-7917.Es.2017.22.13.30494 (2017).
29. Song, L. et al. Efﬁcacious recombinant inﬂuenza vaccines produced by high yield
bacterial expression: a solution to global pandemic and seasonal needs. PLoS
ONE 3, e2257 (2008).
30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent
seasonal ﬂu vaccine comprising recombinant hemagglutinin-ﬂagellin fusion
proteins. Open Forum Infect. Dis. 3, ofw015 (2016).
31. Aguilar-Yanez, J. M. et al. An inﬂuenza A/H1N1/2009 hemagglutinin vaccine
produced in Escherichia coli. PLoS ONE 5, e11694 (2010).
32. Saczynska, V. Inﬂuenza virus hemagglutinin as a vaccine antigen produced in
bacteria. Acta Biochim Pol. 61, 561–572 (2014).
33. Davis, A. R. et al. Immune response to human inﬂuenza virus hemagglutinin
expressed in Escherichia coli. Gene 21, 273–284 (1983).
34. Rosales-Mendoza, S. et al. What does plant-based vaccine technology offer to the
ﬁght against COVID-19? Vaccines 8, 183 (2020).
35. Pillet, S. et al. A plant-derived quadrivalent virus like particle inﬂuenza vaccine
induces cross-reactive antibody and T cell response in healthy adults. Clin.
Immunol. 168, 72–87 (2016).
36. Pillet, S. et al. Immunogenicity and safety of a quadrivalent plant-derived virus
like particle inﬂuenza vaccine candidate-two randomized Phase II clinical trials in
18 to 49 and >/=50 years old adults. PLoS ONE 14, e0216533 (2019).
37. Ward, B. J. et al. Efﬁcacy, immunogenicity, and safety of a plant-derived, quad-
rivalent, virus-like particle inﬂuenza vaccine in adults (18-64 years) and older
adults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396,
1491–1503 (2020).
38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant-